Kabazitaksel

Cabazitaxel, the active ingredient in Kabazitaksel, is a taxane presented as a solution for injection for intravenous use. It is indicated for the treatment of metastatic castration‑resistant prostate cancer in patients whose disease has progressed despite hormonal therapy.

GNH USA supplies Kabazitaksel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable oncology medicines. Clients include hospital pharmacies, cancer treatment centers, and procurement agencies across Europe, Asia and the Americas.

Kabazitaksel (cabazitaxel) is employed in the management of prostate cancer that no longer responds to hormonal therapy.

- Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression. - Post‑docetaxel disease progression: provides an alternative taxane option after failure of first‑line taxane therapy. - Hormone‑refractory prostate cancer: offers cytotoxic activity when androgen‑deprivation therapy is ineffective.

Cabazitaxel therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: decreased white blood cell count increasing infection risk. - Fatigue: generalized tiredness affecting daily activities. - Diarrhea: watery stools that may lead to dehydration. - Nausea: sensation of urge to vomit. - Alopecia: hair loss on scalp and body. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: arrhythmias or reduced left ventricular function. - Hepatotoxicity: elevated liver enzymes or liver failure. - Severe mucositis: painful inflammation of the mouth and gastrointestinal tract.

When using Kabazitaksel, clinicians should observe specific safety measures to minimize risks. - Baseline blood counts: obtain complete blood count before each cycle to monitor neutropenia. - Infection monitoring: watch for signs of fever or infection and treat promptly. - Liver function: assess hepatic enzymes prior to treatment and during therapy. - Concomitant drugs: avoid concurrent use of strong CYP3A4 inhibitors that may increase exposure. - Pregnancy and lactation: contraindicated in pregnant or breastfeeding women due to potential fetal harm. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, requiring careful assessment before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise cabazitaxel plasma levels and increase toxicity. - Concurrent use with other myelosuppressive agents: can exacerbate neutropenia and thrombocytopenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure and efficacy. - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential increased bleeding risk. - Antiemetics containing corticosteroids: may affect immune response; observe for infection signs.